# Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries

> **NCT00366041** · PHASE2 · TERMINATED · sponsor: **Laboratoires Genévrier** · enrollment: 20 (estimated)

## Conditions studied

- Burns

## Interventions

- **DRUG:** Dermal substrate cellularised LG002 (10x10cm)
- **DEVICE:** Dermal substrate uncellularised LG002 (10x10 cm)

## Key facts

- **NCT ID:** NCT00366041
- **Lead sponsor:** Laboratoires Genévrier
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2008-12
- **Final completion:** 2009-12
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** not appropriate to carry on the study
- **Last updated:** 2010-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366041, "Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00366041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*